Efficacy of erlotinib in subsequent lines of non-small cell lung cancer therapy

Abstract

Targeted therapy is becoming more and more important part of bronchial carcinoma treatment. One of the approaches inclides administering erlotinib in later lines of therapy of non-small cell carcinoma.

Our two case studies document a very good therapeutical effect as well as minimal toxicity of such an approach when treating adenocarcinoma (EFGR wild-type) and for squamous carcinoma.

Keywords

• non-small cell lung carcinoma
• targeted treatment
• erlotinib